J&J to settle most lawsuits against hip implant - report
Johnson & Johnson agreed to pay about $1 billion to resolve many lawsuits claiming the company sold defective metal-on-metal hip implants that ultimately had to be removed, according to a report in Bloomberg.
The agreement resolves over 95% of the 6,000 cases in which surgeons extracted the company’s Pinnacle implants because they left patients unable to walk and in pain, according to the report. The $1 billion total includes an earlier settlement for more than $400 million and there are still about 4,500 pending suits by patients with artificial hips that were not made totally of metal or haven’t been surgically removed, Bloomberg added.
Contributor
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
Momentum Indicator for JNJ turns negative, indicating new downward trend
JNJ saw its Momentum Indicator move below the 0 level on September 16, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 83 similar instances where the indicator turned negative. In 37 of the 83 cases, the stock moved further down in the following days. The odds of a decline are at 45%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for JNJ moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 38 similar instances where the indicator moved out of overbought territory. In 16 of the 38 cases, the stock moved lower in the following days. This puts the odds of a move lower at 42%.
The Moving Average Convergence Divergence Histogram (MACD) for JNJ turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 17 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 36%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where JNJ declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 40%.
JNJ broke above its upper Bollinger Band on September 03, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 27 of 52 cases where JNJ's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 52%.
Following a +1.13% 3-day Advance, the price is estimated to grow further. Considering data from situations where JNJ advanced for three days, in 164 of 350 cases, the price rose further within the following month. The odds of a continued upward trend are 47%.
The Aroon Indicator entered an Uptrend today. In 127 of 261 cases where JNJ Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 49%.
Fundamental Analysis (Ratings)
The Tickeron Profit vs. Risk Rating rating for this company is 5 (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 64, placing this stock better than average.
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 12 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (7.657) is normal, around the industry mean (19.050). P/E Ratio (31.321) is within average values for comparable stocks, (34.258). Projected Growth (PEG Ratio) (2.831) is also within normal values, averaging (5.614). Dividend Yield (0.020) settles around the average of (0.025) among similar stocks. P/S Ratio (6.658) is also within normal values, averaging (4.033).
The Tickeron SMR rating for this company is 37 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 40 (best 1 - 100 worst), indicating steady price growth. JNJ’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
an investment holding company with interests in health care products
Industry PharmaceuticalsMajor
Advertisement